BFRIW
Price:
$0.08
Market Cap:
$5.54M
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
Stock Exchange
NASDAQ
Ticker
BFRIW
According to Biofrontera Inc.’s latest financial reports and current stock price. The company's current ROE is -477.13%. This represents a change of 449.90% compared to the average of -86.77% of the last 4 quarters.
The mean historical ROE of Biofrontera Inc. over the last ten years is -181.49%. The current -477.13% ROE has changed 162.90% with respect to the historical average. Over the past ten years (40 quarters), BFRIW's ROE was at its highest in in the June 2021 quarter at 267.81%. The ROE was at its lowest in in the September 2023 quarter at -610.98%.
Average
-181.49%
Median
-188.52%
Minimum
-420.01%
Maximum
36.39%
Discovering the peaks and valleys of Biofrontera Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 15.57%
Maximum Annual ROE = 36.39%
Minimum Annual Increase = -618.06%
Minimum Annual ROE = -420.01%
Year | ROE | Change |
---|---|---|
2023 | -420.01% | 15.57% |
2022 | -2.68% | -99.19% |
2021 | -332.62% | 76.44% |
2020 | -188.52% | -618.06% |
The current ROE of Biofrontera Inc. (BFRIW) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-251.77%
5-year avg
-181.49%
10-year avg
-181.49%
Biofrontera Inc.’s ROE is greater than Biofrontera Inc. (-477.13%), greater than Pasithea Therapeutics Corp. (-74.63%), greater than Inspira Technologies Oxy B.H.N. Ltd. (-134.16%), greater than Bluejay Diagnostics, Inc. (-187.00%), less than NRx Pharmaceuticals, Inc. (193.11%),
Company | ROE | Market cap |
---|---|---|
-477.13% | $5.54M | |
-74.63% | $3.78M | |
-134.16% | $22.70M | |
-187.00% | $1.21M | |
193.11% | $14.89M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Biofrontera Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Biofrontera Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Biofrontera Inc.'s ROE?
How is the ROE calculated for Biofrontera Inc. (BFRIW)?
What is the highest ROE for Biofrontera Inc. (BFRIW)?
What is the 3-year average ROE for Biofrontera Inc. (BFRIW)?
What is the 5-year average ROE for Biofrontera Inc. (BFRIW)?
How does the current ROE for Biofrontera Inc. (BFRIW) compare to its historical average?